CNBC Pro

Eli Lilly obesity drug delivers 20% weight loss, bolstering investment case for new therapies

A woman walks down the street on Michigan Avenue in Chicago, Illinois.
Jeff Haynes | AFP | Getty Images

Clinical trial data released Thursday by Eli Lilly reinforces the belief that a wave of obesity treatments are on the horizon that could be gamechangers for patients struggling to lose weight and perhaps investors as well.

More In Investing trends

CNBC ProThree stocks to play the clean tech theme after Biden signed the largest climate bill in U.S. history
CNBC ProStocks including Honeywell and Emerson are under-the-radar beneficiaries of the climate bill
CNBC ProGoldman Sachs says planned energy transition is driving stocks, picks its 'best-in-class' names